Crenolanib is a second-generation FLT3 inhibitor that is now being tested in clinical studies for its safety and efficacy in the treatment of several cancers, including acute myeloid leukemia (AML) and gastrointestinal stromal tumors (GIST). This evidence concerns the gene FLT3 and gastrointestinal stromal tumor.